SCHEMBL2434560

SCHEMBL2434560

Cn1c(=O)c(C(=O)CCC(=O)O)c(O)c2cc(C3CCCC3)cnc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 9/20 0.47
PKMYT1 Q99640 1/20 0.36
CNR2 P34972 2/20 0.34
ALDH1A1 P00352 1/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
HIF1A Q16665 2/20 0.33
GAA P10253 1/20 0.33
PPARG P37231 1/20 0.33
NCOA2 Q15596 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GLA P06280 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GRIN1 Q05586 1/20 0.31
GRIN2B Q13224 1/20 0.31
FABP4 P15090 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2437750 0.99 EGLN1 (0.46) EGLN1PKMYT1CNR2ALDH1A1NPC1
SCHEMBL2439333 0.91 EGLN1 (0.44) EGLN1PKMYT1CNR2
SCHEMBL2439467 0.88 CNR2 (0.37) EGLN1PKMYT1CNR2ALDH1A1NPC1
SCHEMBL2444418 0.87 EGLN1 (0.43) EGLN1PKMYT1CNR2
SCHEMBL2443365 0.86 EGLN1 (0.42) EGLN1CNR2RAB9AKDM4EKMT2A
SCHEMBL2439526 0.85 EGLN1 (0.43) EGLN1CNR2ALDH1A1RAB9AGAA
SCHEMBL2577077 0.83 EGLN1 (0.49) EGLN1HIF1A
SCHEMBL12291858 0.81 EGLN1 (0.53) EGLN1PKMYT1ALDH1A1NPC1RAB9A
SCHEMBL2434564 0.80 EGLN1 (0.52) EGLN1ALDH1A1NPC1RAB9AHIF1A
SCHEMBL2443706 0.80 EGLN1 (0.52) EGLN1ALDH1A1NPC1RAB9AHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142509-B1 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP claimed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US claimed
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2011-09-15 US claimed
EP-2142509-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE Amgen, Inc (US) 2010-01-13 EP claimed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US claimed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO claimed
EP-2142509-B1 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC (US) 2013-12-04 EP disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8349868-B2 Azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2013-01-08 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-8048894-B2 Quinolones and azaquinolones that inhibit prolyl hydroxylase AMGEN INC. (US) 2011-11-01 US disclosed
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2011-09-15 US disclosed
EP-2142509-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE Amgen, Inc (US) 2010-01-13 EP disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase AMGEN INC. (US) 2009-06-18 US disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed
WO-2008130600-A2 QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE AMGEN INC. (US) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156605-A1 Quinolones and azaquinolones that inhbit prolyl hydroxylase EGLN3, HIF1AN, EGLN2 EGLN1 6/4885PKMYT1 3631/4885CNR2 3714/4885
US-20110224248-A1 AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE HIF1AN, EGLN3, EGLN2 EGLN1 6/4885PKMYT1 3806/4885CNR2 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.